Body Pharm BPC 157 & TB500 32 Pen

Body Pharm BPC-157 & TB-500 32 Pen: Buy Now on JCSG.org

The Body Pharm BPC-157 & TB-500 32 pen is a premium dual-peptide research device containing 16 mg BPC-157 and 16 mg TB-500 (32 mg total peptide) split across 32 actuations, delivering a precise 0.5 mg + 0.5 mg per click [1][2]. Order yours now using the buy box above — JCSG.org ships authentic Body Pharm stock directly to UK researchers. This guide maps the two peptides' complementary mechanisms — BPC-157's modulation of the nitric oxide pathway and VEGF upregulation against TB-500's G-actin sequestration and angiogenic signalling — directly onto that 32-dose format [2].

Combination evidence remains thin: as of 2026, no peer-reviewed animal study published 2020–2026 has formally evaluated the two peptides together in a controlled in vivo model, and TB-500 itself has zero registered human clinical trials [3][5]. Everything below is framed for laboratory research context.

Key Takeaways

• Available now on JCSG.org — add to cart using the buy box above and receive authentic Body Pharm stock with batch-specific COA.
• The 32-pen format delivers 0.5 mg BPC-157 + 0.5 mg TB-500 per actuation across 32 doses, removing reconstitution variability in research settings.
• BPC-157 and TB-500 reach angiogenesis through distinct pathways: nitric oxide signalling and growth-factor upregulation versus G-actin sequestration and cytoskeletal remodelling.
• No peer-reviewed combination animal trial exists; synergy remains a working hypothesis.
• Lot-specific Certificates of Analysis documenting HPLC purity (≥98%), mass spectrometry, sterility and endotoxin levels are available on request.
• BPC-157 and TB-500 are unlicensed medicinal products in the UK; supplied for bona fide laboratory research only.

What Is the Body Pharm BPC-157 & TB-500 32 Pen?

The Body Pharm BPC-157 & TB-500 32 pen is a pre-mixed, multi-dose research delivery device containing 16 mg BPC-157 research peptide and 16 mg TB-500 peptide in a single pen, dispensed across 32 actuations for a nominal 0.5 mg + 0.5 mg per click [1][2]. Body Pharm manufactures the device for the UK research market (reference: bodypharm.co.uk), supplied as research use only (RUO) [2]. JCSG.org is your trusted UK reseller — order today via the buy box above for fast UK dispatch.

In UK research communities the device is frequently referred to as the "Wolverine Stack", a nickname tied to the dual-peptide tissue-repair rationale rather than any clinical indication [1].

How it differs from other formats

The pen format pre-loads both peptides in solution, removing the reconstitution step required by lyophilised vials and the separate-syringe handling required when running BPC-157 and TB-500 from individual single-peptide pens. This reduces operator-dependent variability in dose preparation, which matters for reproducibility in longitudinal studies [1].

Total peptide load (32 mg) sits at the high end of the combination-pen format range, well above lower-strength 5 mg + 5 mg or 10 mg + 10 mg configurations. That difference changes the per-click mg figure and therefore the protocol arithmetic researchers need to apply when planning a study [1][2]. Use the buy box above to secure this high-load format through JCSG.org.

Some researchers prefer lyophilised vials because they offer longer shelf stability and allow independent titration of each peptide. The pen's fixed 1:1 ratio is a real constraint if you need to vary the BPC-157 to TB-500 proportion.

BPC-157 and TB-500: Distinct Mechanisms, Shared Targets

BPC-157 and TB-500 act on tissue repair through non-overlapping molecular routes that converge on vascular and cytoskeletal endpoints. BPC-157 drives nitric oxide signalling and growth factor upregulation in endothelial and mucosal cells, while TB-500 sequesters monomeric G-actin and promotes angiogenesis via Thymosin β4-derived activity [2][5]. Both mechanisms share VEGF-mediated angiogenesis as a downstream target but reach it through separate upstream pathways.

BPC-157: NO pathway and growth factor upregulation

BPC-157 is a 15-amino-acid synthetic peptide derived from a protective sequence identified in human gastric juice protein [2]. UK-facing technical descriptions characterise its primary mechanism as modulation of the nitric oxide system to maintain vascular function and tissue perfusion, alongside upregulation of VEGF and EGF receptor signalling on endothelial and mucosal cells [2]. Most of the cited mechanistic work comes from pre-2020 Croatian rodent gastroprotection and vascular-injury models; 2020–2026 literature largely summarises rather than re-tests those NO-pathway findings, and the underlying primary citations are not restated in the sources reviewed here [5].

The clinical evidence base is thin. As of 2026, published reviews identify one small Phase I safety study and a small intra-articular knee study for BPC-157 research peptide, plus two registered oral inflammatory bowel disease trials without published efficacy data, and no completed Phase II or Phase III efficacy trials [5][4].

Mechanistic findings from rodent models do not automatically translate to human physiology, and the absence of Phase II efficacy data limits confidence in any proposed clinical benefit.

TB-500: G-actin sequestration and angiogenesis

TB-500 is commercially described as a synthetic fragment of Thymosin β4 (encoded by the TMSB4X gene), conventionally mapped to amino acids 17–23 of the 43-residue parent protein, though that exact 17–23 designation is not consistently confirmed in 2020–2026 peer-reviewed literature [5]. Its principal mechanism is interaction with G-actin to sequester monomeric actin, regulating cytoskeletal dynamics and cellular migration; secondary effects include VEGF-mediated angiogenesis and anti-inflammatory cytokine modulation [2][5].

Current mechanistic discussion of TB-500 peptide still leans on foundational Thymosin β4 biochemistry, including the LKKTET actin-binding motif, rather than new TB-500-specific primary papers [2]. A 2024 medical review notes emerging data suggesting a smaller degradation fragment may mediate part of the activity attributed to the parent molecule, complicating clean attribution to a single active site [5]. Human clinical evidence is effectively absent: published commentary records zero registered human trials of TB-500 itself, and even parent Thymosin β4 did not progress through full regulatory approval [5][4].

With no human trial data, any proposed benefit remains theoretical. TB-500 is an exploratory target, not an established therapeutic.

Why Combine BPC-157 and TB-500? The Mechanistic Rationale

The combination rationale rests on pathway complementarity: TB-500 drives cytoskeletal remodelling and angiogenesis through G-actin sequestration and VEGF-mediated vessel formation, while BPC-157 acts on the nitric oxide system to support endothelial integrity and upregulates growth factors that scaffold matrix repair [2]. The two peptides converge on VEGF upregulation via distinct upstream routes, which is the mechanistic basis for the additive-signalling hypothesis researchers test in preclinical models.

No completed peer-reviewed animal study published 2020–2026 has formally evaluated BPC-157 and TB-500 in combination in a controlled in vivo model [3]. The synergy argument is an extrapolation from individual single-peptide data and from broader protein–peptide interaction theory, not a head-to-head trial outcome. The "Wolverine Stack" label that recurs on UK and international reseller pages in 2024 reflects practitioner-level recognition of this proposed complementarity rather than any registered combination study [4].

Where the pathways diverge and where they meet

TB-500 acts upstream on the cytoskeleton: by sequestering monomeric G-actin via the LKKTET-region biochemistry of parent Thymosin β4, it modulates the actin polymerisation equilibrium that governs cell migration into wound beds, with downstream VEGF release supporting capillary sprouting [2]. BPC-157, by contrast, is described in 2024 technical summaries as modulating the NO system to maintain vascular function and tissue perfusion while upregulating VEGF and additional growth factors implicated in fibroblast and tenocyte activity [2]. Both routes terminate at angiogenesis, which is the convergence point the combination thesis exploits.

BPC-157's reported cytoprotective effects on gastric and mucosal linings, drawn from pre-2020 Croatian rodent work [2], are sometimes invoked as a tolerability rationale in research models involving oral co-administration or systemic stress [2]. That claim is mechanistic, not clinical: no human safety data confirm a mucosal-protective benefit specific to the combination.

Mechanistic summary

• TB-500 primary action: G-actin sequestration → cell migration, VEGF-mediated angiogenesis [2]
• BPC-157 primary action: NO pathway modulation, growth-factor upregulation, endothelial support [2]
• Convergent target: VEGF upregulation via two distinct upstream routes [2]
• Evidence status (2026): Zero peer-reviewed combination animal trials indexed; synergy is hypothesis-level [3]

For further reading, JCSG's overviews of how protein–peptide interactions shape cellular function and understanding protein–peptide interactions contextualise the binding-interface logic behind both molecules. The structural basis of peptide–actin and peptide–receptor binding clarifies why the two mechanisms are predicted to be complementary rather than redundant.

Researchers designing combination protocols should treat the additive-angiogenesis model as a working hypothesis to be tested, not an established finding.

The 32-Dose Pen Format: Per-Dose Breakdown

The Body Pharm BPC-157 & TB-500 32 pen contains 32 mg of total peptide split evenly as 16 mg BPC-157 and 16 mg TB-500, giving a nominal per-actuation dose of approximately 0.5 mg BPC-157 plus 0.5 mg TB-500 (1.0 mg total) if the device is dispensed across all 32 clicks [2][1]. The manufacturers' public materials do not always specify the exact µL per click, so the 1.0 mg per-dose figure is a simple division of label content and should be reconciled against the printed concentration on any given batch before a protocol is finalised [2].

Body Pharm BPC-157 + TB-500 Pen: Format Specifications

The 32-dose pen delivers a large total peptide load in a single ready-to-use device, offering a longer experimental window per unit than lower-strength formats. Add to cart now via the buy box at the top of this page.

Why pre-mixed pens in research settings

A pre-mixed pen removes two error-prone steps from the workflow: reconstitution of lyophilised powder with bacteriostatic water, and manual syringe draw against a target unit mark. For longitudinal rodent protocols where consistent per-administration dosing is a confound to control, removing reconstitution variance between operators is methodologically useful because it reduces batch-to-batch and operator-dependent variability that can obscure true biological effects [1].

The trade-off is reduced flexibility: the BPC-157 to TB-500 ratio is fixed at 1:1, which suits the convergent-angiogenesis hypothesis discussed above but constrains any researcher wanting to titrate the two molecules independently. For single-peptide work where ratio control matters, the individual BPC-157 research peptide and TB-500 peptide reference pages set out the lyophilised-vial alternative.

Research Protocol Reference: Dosage and Administration

The parameters below summarise rodent-model and in vitro reference points drawn from published literature on BPC-157 and TB-500 individually. They are not dosing instructions for human use and are reproduced strictly for research planning. No peer-reviewed animal study published 2020–2026 has formally evaluated the BPC-157 + TB-500 combination in a controlled in vivo model [3], so any combination protocol is an extrapolation from single-peptide work.

RUO disclaimer. This material is for research use only. The products discussed are not licensed medicines in the United Kingdom. Administration to humans falls outside the scope of this reference and may fall within MHRA enforcement against unlicensed medicinal products.

Reference parameters from published animal literature

Tendon-specific rodent protocols with transparent mg/kg subcutaneous regimens for these exact commercial fragments are sparsely indexed post-2020. Most secondary summaries trace back to pre-2020 Zagreb-group work or non-fragment-specific Tβ4 literature [1][3]. Any precise µg/kg/day figure should be treated as extrapolated rather than standardised: the original studies often did not report exact molecular-weight-normalised doses, or used parent Thymosin β4 rather than the TB-500 fragment.

Storage of the pen format

Store the device at 2–8 °C in its original carton, protected from light, and return it to refrigeration promptly after each actuation. Avoid freezing the reconstituted solution because freeze-thaw cycles promote peptide aggregation and loss of bioactivity. Record batch number, first-use date and per-actuation volume against the labelled concentration so that mg-per-dose can be recalculated for each lot.

Evaluating Research Peptide Quality: COA and Purity

A Certificate of Analysis (COA) for a research peptide pen should document four parameters at minimum: HPLC (High-Performance Liquid Chromatography) purity percentage, mass spectrometry confirmation of molecular weight against the theoretical mass, sterility testing results for the reconstituted solution, and bacterial endotoxin levels expressed in EU/mg. Without all four, the document is a marketing summary rather than a release specification. Each parameter independently confirms a different aspect of product integrity: purity confirms the proportion of correctly synthesised sequence, mass spectrometry confirms the identity of that sequence, sterility confirms the absence of microbial contamination, and endotoxin levels confirm the absence of pyrogenic bacterial fragments [3].

HPLC purity of ≥98% is the functional threshold treated as research-grade in UK peptide procurement discussions as of 2025–2026 [3][4]. The practical gap between a 98% and a 99%+ lot is the proportion of truncated sequences, deletion peptides and synthesis by-products carried into the assay. For dose-response work or any study where reproducibility across batches matters, that 1–2% delta can shift effective peptide mass per actuation and confound interpretation, because the impurities may have different biological activity or may compete for the same cellular targets [1]. Sub-98% material has been associated with heavy-metal contaminants including arsenic and lead in 2024 commentary on peptide quality [4]. JCSG.org lists batch-specific COA documentation for every Body Pharm pen — check the product page for the current lot details.

Batch-specific documentation

Request a COA tied to the specific lot number on the pen carton, not a generic specimen document. Generic COAs do not evidence that the particular batch in hand was tested, because manufacturing variability between lots can affect purity, endotoxin load and sterility status [1]. The lot-specific record should match the batch printed on the device and carry a test date that precedes the dispatch date.

RUO designation means the product is not licensed as a medicinal product and is not manufactured under the GMP (Good Manufacturing Practice) regime the MHRA applies to licensed medicines. Body Pharm is the manufacturer of this device [2]; RUO material is explicitly exempt from GMP oversight, which is why lot-specific batch documentation is essential regardless of where you source the pen.

Researchers concerned about batch variability should request multiple lot-specific COAs before committing to a large order, since purity and endotoxin levels can drift between manufacturing runs.

UK Regulatory Context for Research Peptides in 2026

BPC-157 and TB-500 sold in the UK are unlicensed medicinal products when presented for administration to humans, and the Research Use Only (RUO) designation does not exempt a product from MHRA jurisdiction if marketing or supply implies human use [2]. RUO material is not manufactured under the GMP framework the MHRA applies to licensed medicines, has not been assessed for safety or efficacy in humans, and is permissible only for legitimate in vitro or laboratory research within an appropriately controlled setting. The RUO label is a statement of intended use, not a regulatory exemption [1].

As of 2025–2026, MHRA public communications on unlicensed medicines indicate that injectable peptides advertised for cosmetic, wellness or gym-market purposes fall within medicines regulation regardless of RUO labelling, with enforcement tools including warning letters, product seizures and referral for criminal investigation [2][1]. Every result on the current UK SERP for the combination pen carries an RUO or "not for human consumption" disclaimer, which reflects vendor risk posture rather than regulatory clearance.

Verifying current position

Before placing an order, check the MHRA's most recent guidance on unlicensed medicines and peptide enforcement, since the position can shift between editions of this guide. Nothing here constitutes legal advice. Procurement staff handling the BPC-157 research peptide or TB-500 peptide lines should document the research purpose, the receiving laboratory and the named principal investigator on the internal purchase record. Written documentation of legitimate research intent is the primary defence against enforcement action if a supplier is later found to have diverted product to unlicensed human use [2].

How the BPC-157 + TB-500 Pen Fits a Broader Research Stack

Researchers studying tissue repair and angiogenesis frequently run the BPC-157 and TB-500 lines alongside other targets that interrogate complementary pathways. The combination pen sits naturally within a wider programme covering matrix remodelling, mitochondrial signalling and redox cofactor biology, rather than as a standalone investigation. Browse the full range of Body Pharm peptides available on JCSG.org.

Adjacent research targets

GHK-Cu is studied for copper-dependent collagen and elastin synthesis, providing a matrix-deposition counterpart to the migration and angiogenesis axes covered by BPC-157 and TB-500. Collagen cross-linking and fibre assembly are the structural endpoint of the tissue-repair cascade that BPC-157 and TB-500 initiate [1].

MOTS-C, available in a comparable 32-dose pen format, is investigated for mitochondrial-derived peptide signalling and AMPK (Adenosine Monophosphate-Activated Protein Kinase)-linked metabolic readouts. Cellular energy status constrains the biosynthetic capacity required for sustained angiogenesis and matrix synthesis [1].

NAD+, supplied in the 1000 mg pen, supports research into sirtuin activity and cellular repair cofactor pools. NAD+-dependent deacetylases regulate the transcriptional programmes that drive fibroblast and endothelial differentiation [1].

For laboratories mapping peptide candidates back to underlying structural biology, the structural genomics to peptide therapeutics context outlines how solved protein structures inform fragment-based research design. No clinical claims attach to any of these targets under RUO supply.

Frequently Asked Questions

What is the difference between a pre-mixed pen and a lyophilised vial?

A pre-mixed pen contains peptide already reconstituted in sterile diluent and sealed in a multi-dose cartridge, whereas a lyophilised vial supplies dry powder that the researcher must reconstitute with bacteriostatic water before use. The pen format reduces handling variability and reconstitution error because the solvent volume and peptide concentration are fixed at manufacture. Lyophilised vials require accurate solvent measurement at the bench and carry the risk of under- or over-reconstitution [1]. Lyophilised vials offer longer shelf stability before opening.

What does '32 doses' mean in practice for a research study?

The Body Pharm pen is engineered as a 32-actuation device containing 16 mg BPC-157 and 16 mg TB-500, giving a nominal 0.5 mg + 0.5 mg per click if all 32 actuations are dispensed evenly [5][6]. For a study running daily administration, one pen covers roughly 32 days of in vitro or in vivo dosing per subject because each actuation delivers a fixed volume and peptide mass.

Where can I buy the BPC-157 + TB-500 pen in the UK?

Order directly on JCSG.org — use the buy box at the top of this page to add the Body Pharm BPC-157 & TB-500 32 pen to your cart now. JCSG.org supplies authentic Body Pharm stock to UK research addresses with competitive pricing (see the current price in the buy box above). BPC-157 and TB-500 are unlicensed medicinal products in the UK and may only be supplied for bona fide laboratory research use, not for human administration. The MHRA treats injectable peptides presented for human use as unlicensed medicines regardless of "research use only" labelling [2].

What purity level should a research-grade peptide pen have?

UK procurement discussions in 2023–2025 functionally treat ≥98% HPLC purity as the minimum acceptable threshold for injectable research peptides, with premium lots advertised at ≥99% or ≥99.5% [7]. Sub-98% material has been associated with heavy-metal contamination in some preparations and is generally restricted to early-stage in vitro work because the impurities can interfere with dose-response relationships and confound mechanistic interpretation [1].

Has the BPC-157 + TB-500 combination been tested in human clinical trials?

No. As of 2026, there are no completed Phase II or Phase III human trials for the BPC-157 + TB-500 combination, nor any indexed peer-reviewed combination animal studies published 2020–2026 [1][2]. BPC-157 has one small Phase I safety trial and limited early-phase entries; TB-500 has zero registered human trials [1].

How should the pen be stored?

Store the pen refrigerated at 2–8 °C, upright, protected from light, and away from the freezer compartment to prevent peptide aggregation from freeze-thaw cycles. Repeated freezing and thawing denatures peptides and reduces bioactivity [1]. Record the first-use date on the cartridge and confirm batch concentration against the certificate of analysis before calculating per-click mass for any documented protocol.

Order the Body Pharm BPC-157 + TB-500 32 Pen on JCSG.org

Ready to add this to your research programme? Use the buy box at the top of this page to place your order now — JCSG.org ships authentic Body Pharm stock to UK research addresses with batch-specific COA available on request. See the current price in the buy box above; no price-comparison guesswork needed.

Before use, confirm that your receiving laboratory has documented research protocols in place, a named principal investigator, and written approval from your institution's research governance body. Verify that the lot-specific Certificate of Analysis documents HPLC purity ≥98%, mass spectrometry identity confirmation, negative sterility testing, and endotoxin levels below 5 EU/mg. Cross-check the batch number on the carton against the COA before use. If you are designing a combination protocol, treat the additive-angiogenesis hypothesis as a working model to be tested rather than an established finding, and consult the single-peptide reference pages for BPC-157 and TB-500 to ground your dosing parameters in published animal literature.

Add the BPC-157 + TB-500 32 pen to your cart on JCSG.org →

For research use only. Not for human consumption or clinical administration.